5′-Homoneplanocin A inhibits hepatitis B and hepatitis C

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 5043-5046

  Yang, Minmin ^a   Schneller, Stewart W ^a   Korba, Brent ^b  

^a AUBURN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' HOMONEPLANOCIN A; ALPHA INTERFERON; ANTIVIRUS AGENT; LAMIVUDINE; RIBAVIRIN; UNCLASSIFIED DRUG; 5' HOMONEPLANOCIN; 5'-HOMONEPLANOCIN; ADENOSINE; DRUG DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRION; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; CHEMISTRY; DRUG EFFECT; PHYSIOLOGY; STEREOISOMERISM; SYNTHESIS;

ADENOSINE; ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HEPATITIS B VIRUS; HUMANS; STEREOISOMERISM; VIRUS REPLICATION;

EID: 22744440966     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058200e     Document Type: Article

References (24)

1. Recent Advances in Nucleosides: Chemistry and Chemotherapy; Chu, C. K., Ed.; Elsevier Science: Amsterdam, 2002.
2. (a) Schneller, S. W. Carbocyclic nucleosides (carbanucleosides) as therapeutic leads. Curr. Top. Med. Chem. 2002, 2, 1087-1092.
3. (b) Rodriguez, J. B.; Comin, M. J. New progresses in the enantioselective synthesis and biological properties of Carbocyclic nucleosides. Mini-Rev. Med. Chem. 2003, 3, 95-114.
4. (a) Wolfe, M. S.; Borchardt, R. T. S-Adenosyl-L-homocysteine hydrolase as a target for antiviral chemotherapy. J. Med. Chem. 1991, 34, 1521-1530.
5. (b) Moon, H. R.; Choi, W. J.; Kim, H. O.; Jeong, L. S. Preparative synthesis of the key intermediate, (4R,5R)-3-benzyloxymethyl-4,5- isopropylidenedioxycyclopent-2-enone for Carbocyclic nucleosides. Chem. Lett. 2004, 33, 506-507.
6. Borchardt, R. T.; Keller, B. T.; Patel-Thombre, U. Neplanocin, A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J. Biol. Chem. 1984, 259, 4353-4358.
7. (a) Hasobe, M.; McKee, J. G.; Borcherding, D. R.; Borchardt, R. T. 9-(trans-2′,trans-3′-Dihydroxycyclopent-4′-enyl)adenine and 9-(trans-2′-trans-3′-dihydroxycyclopent-4′-enyl) -3-deaza-adenine: analogs of neplanocin A, which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob. Agents Chemother. 1987, 31, 1849-1851.
8. (b) Paisley, S. D.; Hasobe, M.; Borchardt, R. T. Elucidation of the mechanism by which 9-(trans-2′-trans-3′-dihydroxycyclopent-4′- enyl)adenine inactivates S-adenosylhomocysteine hydrolase and elevates cellular levels of S-adenosylhomocysteine. Nucleosides Nucleotides 1989, 8, 689-698.
9. Jeong, L. S.; Park, J. G.; Choi, W. J.; Moon, H. R.; Lee, K. M.; Kim, H. O.; Kim, H.-D.; Chun, M. W.; Park, H.-Y.; Kim, K.; Sheen, Y. Y. Synthesis of halogenated 9-(dihydroxycyclopent-4′-enyl) adenines and their inhibitory activities against S-adenosylhomocysteine hydrolase. Nucleosides Nucleotides Nucleic Acids 2003, 22, 919-921.
10. Shuto, S.; Obara, T.; Saito, Y.; Andrei, G.; Snoeck, R.; De Clercq, E.; Matsuda, A. New neplanocin analogues. 6. Synthesis and potent antiviral activity of 6′-homoneplanocin A. J. Med. Chem. 1996, 39, 2392-2399.
11. Yang, M.; Ye, W.; Schneller, S. W. Preparation of Carbocyclic S-adenosylazamethionine accompanied by a practical synthesis of (-)-aristeromycin. J. Org. Chem. 2004, 69, 3993-3996.
12. (a) Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
13. (b) Hughes, D. L. Progress in the Mitsunobu reaction. A review. Org. Prep. Proced. Int. 1996, 28, 127-164.
14. 7 4.
15. Trost, B. M.; Salzman, T. N.; Hiroi, K. New synthetic reactions. Sulfenylations and dehydrosulfenylations of esters and ketones. J. Am. Chem. Soc. 1976, 98, 4887-4902.
16. 13C NMR spectral analysis of 8, which gave an apparent triplet for the ring carbonyl (rather than a quartet or multiplet that would have been seen had the double bond been exocyclic).
17. Luche, J. L. Lanthanides in organic chemistry. 1. Selective 1,2 reductions of conjugated ketones. J. Am. Chem. Soc. 1978, 100, 2226-2227.
18. Karayiannis, P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 2003, 51, 761-785.
19. (a) Fargion, S.; Fracanzani, A. L.; Valenti, L. Treatment choices for people infected with HCV. J. Antimicrob. Chemother. 2004, 53, 708-712.
20. (b) Gordon, C. P.; Keller, P. A. Control of hepatitis C: A medicinal chemistry perspective. J. Med. Chem. 2005, 48, 1-20.
21. For a leading reference on the procedures used for these assays, see: Yang, M.; Schneller, S. W. Bioorg. Med. Chem. Lett. 2005, 15, 149-151.
22. Korba, B. E.; Gerin, J. L. Use of a standardized cell culture assay to determine activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 1992, 19, 55-70.
23. Blight, K. J.; Kolykhalov, A. A.; Rice, C. M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290, 1972-1974.
24. Okuse, C.; Rinaudo, J. A.; Farrar, K.; Wells, F.; Korba, B. E. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res., in press.